Endotoxin and immune activation in chronic heart failure: A prospective cohort study

Lancet

Volumn 353, Issue 9167, 1999, Pages 1838-1842

  Niebauer, Josef ^a   Volk, Hans Dieter ^b   Kemp, Michael ^c   Dominguez, Martin ^d   Schumann, Ralf R ^e   Rauchhaus, Mathias ^c   Poole Wilson, Philip A ^f   Andrew, J ^a   Coats, S ^a   Anker, Stefan D ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Heart Science Center   (United Kingdom)

^e HAREFIELD HOSPITAL   (United Kingdom)

^f MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BIOCHEMICAL MARKER; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTOXIN; LIPOPOLYSACCHARIDE; NITRATE;

ADULT; AGED; ARTICLE; BACTERIAL TRANSLOCATION; BIOCHEMISTRY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; EDEMA; ENDOTOXEMIA; FEMALE; HEART FAILURE; HUMAN; HYPOTHESIS; IMMUNITY; INFLAMMATION; INTESTINE MUCOSA PERMEABILITY; MALE; PRIORITY JOURNAL;

EID: 0033614672     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)09286-1     Document Type: Article

References (27)

1. Levine B, Kaiman J, Mayer L, Filllt HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N EnglJMed 1990; 323: 236-41.
2. Anker S D, Swan JW, Chua TP, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: the importance of cardiac cachexia. Circulation 1997; 96: 526-34.
3. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-11.
4. Anker SD, Egerer K, Volk H-D, Kox WJ, Poole-Wilson PA, Coats AJS. Elevated soluble CD 14 receptors and altert cytokines in chronic heart failure. Am J Cardiol 1997; 79: 1426-30.
5. Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249:429-31.
6. Tobias PS, Soldau K, lovine NM, Eisbach P, Weiss P. Lipopolysaccharide (LPS) binding proteins BPI and LBP from different types of complexes with LPS. J Biol Chem 1997; 272:18682-85.
7. Lamping N, Dettmer R, Schroder NWJ, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998; 101:2065-71.
8. Ziegler-Heitbrock, Ulevitch RJ. CD 14: cell surface receptor and differentiation marker. Immunol Today 1993; 14: 121-25.
9. Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coü Cardiol 1996; 28: 1092-102.
10. S autner T, Wessely C, Riegler M, et al. Early effects of catecholamine therapy on mucosal integrity, intestinal blood flow, and oxygen metabolism in porcine endotoxin shock. Ann Surg 1 998; 228: 239-48.
11. Lamping N, Hoess A, Yu B, et al. Effect of site-directed mutagenisis of gasic residues (Arg 94, Lys 95, Lys 99) of lipopolysaccharide (LPS)binding protein on binding and transfer of LPS and subsequent immune cell activation. J Immunol 1996; 157:4648-56.
12. Assicot M, Gendrel D, Carsin H, Raymond], Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515-18.
13. Yang RB, Mark MR, Gray A, et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998; 395: 284-88.
14. Gomez-Jimenez J, Salgado A, Mourelle M, et al. L-arginine: nitric oxide pathway in endotoxemia and human septic shock. Grit Care Med 1995; 23:253-58.
15. Vanderheyden M, Kersschot E, Paulus WJ. Pro-inflammatory cytokines and endothelium-dependentvasodilation in the forearm: serial assessment in patients with congestive heart failure. Eur Heart J 1998; 19:747-52.
16. Vonhof S, Brost B, Stille-Siegener M, Grumbach IM, Kreuzer H, Figulla HR. Monocyte activation in congestive heart failure due to coronary artery disease and idiopathic dilated cardiomyopathy. Int J Cardiol 1998; 63: 237-44.
17. Wagner DR, McTiernan C, Sanders VJ, Feldman AM. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factoralpha in the failing human heart. Circulation 1998; 97: 521-24.
18. Keel M, SchregenbergerN, Steckholzer U, et al. Endotoxin tolerance after severe injury and its regulatory mechanisms. J Trauma 1996; 41 : 430-37.
19. Randow F, Syrbe U, Meisel C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor beta. J Exp Med 1995; 181: 1887-92.
20. Anker SD, Clark AL, Kemp M, et al. Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30: 997-1001.
21. Lew WY, Ryan J, Yasuda S. Lipopolysaccharide induces cell shrinkage in rabbit ventricular cardiac myocytes. Am J Physiol 1997; 272: H2989-93.
22. Starr RG, Lader AS, Phillips GC, Stroman CE, Abel FL. Direct action of endotoxin on cardiac muscle. Shock 1995; 3: 380-84.
23. Munger MA, Johson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of pro inflammatory cytokines in mild or moderate heart failure secondary to ischémie or idiopathic dilated cardiomyopathy. AmJ Cardiol 1996; 77:723-27.
24. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1 998; 31 : 1352-56.
25. Anker SD, Volterrani M, Egerer KR, et al. Tumor necrosis factor alpha as a predictor of peak leg blood flow in patients with chronic heart failure. QJ Med 1998; 91: 199-203.
26. Yan SF, Tritto I, Pinsky D, et al. Induction of interleukin-6 (IL-6) by hypoxia in vascular cells. J Biol Chem 1995; 270: 11463-71.
27. Eggesbo JB, Hjermann I, Lund PK, Joo GB, Ovstebo R, Kierulf P. LPS-induced release of IL-1 beta, IL-6, IL-8,TNF-alpha and sCD14 in whole blood and PBMC from persons with high or low levels of HDLlipoprotein. Cytokine 1994; 6: 521-29.